Pharmacogenomics in the Treatment of Multiple Sclerosis: A

Guide to Siponimod

Paige Willms
Abstract
​Pharmacogenomics is the study of personalized medicine based on a person's DNA. With a greater understanding of DNA in our modern society, pharmacogenomics is quickly changing the way we treat diseases. A new pharmacogenomic medication being used in the treatment of Multiple Sclerosis (MS) is siponimod (Mayzent). Mayzent has been approved as the first oral medication to treat secondary progressive MS with active disease. This is an important medication that may help to close the gap in therapy for patients who suffer from secondary progressive MS.
Full Text
arxch_pdf.pdf
File Size: 276 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH